[Preemptive antimycotic therapy in critically ill patients]

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Pharmacology

Context:

• Surgical intensive care units (ICUs) present high risks for invasive yeast infections.
• Patients with numerous risk factors (≥10 points) are particularly vulnerable to candidiasis.
• Previous studies have not fully established preemptive strategies for this demographic.

Purpose:

• To evaluate the efficacy of preemptive itraconazole treatment in preventing yeast infections and sepsis.
• To assess the impact of preemptive antifungal therapy on patient outcomes in a high-risk surgical ICU population.
• To determine the incidence of invasive yeast infections and candidemia in patients receiving preemptive itraconazole versus standard care.

Summary:

• A study involving 147 high-risk surgical ICU patients (≥10 risk factors) compared preemptive itraconazole treatment (87 patients) with no antifungal treatment (60 patients).
• The itraconazole group showed no positive yeast cultures or cases of candidal sepsis.
• The control group experienced six cases (10%) of positive hemoculture or yeast sepsis, indicating a higher incidence of invasive fungal infection.

Impact:

• Preemptive itraconazole therapy demonstrated a significant reduction in the development of yeast infections and invasive candidal sepsis.
• The findings suggest itraconazole is a viable strategy for preventing invasive fungal infections in critically ill surgical patients.
• This research supports the implementation of targeted antifungal prophylaxis in high-risk ICU populations to improve patient safety and outcomes.